Axsome Therapeutics Provides Year End 2018 Clinical Update

Posted December 27, 2018 by CognitionDev

filed under: Nasdaq

In the News

February 6, 2019

Axsome Therapeutics Receives FDA Agreement under Special Protocol Assessment (SPA) for the MOMENTUM Phase 3 Trial of AXS-07 in Migraine

January 30, 2019

Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy

January 7, 2019

Axsome Therapeutics Raises $23.3 Million Under Existing ATM Facility

See All News